This study was supported by research funding from the National Natural Science Foundation of China (82230006, 82300169, 81970130, 82470159, and U24A20678), the Overseas Expertise Introduction Project ...
Acute promyelocytic leukemia (APL) is classically driven by the PML-RARA fusion oncogene and characterized by a maturation arrest of myeloid precursors. Variant APL (vAPL) with alternative RARA ...
Patients who do not carry any of the aforementioned defining genetic alterations or whose pretreatment cytogenetic investigation fails are categorized into AML subtypes defined by differentiation. 7 ...
The three approved JAK inhibitors (ruxolitinib, fedratinib, and pacritinib) are the cornerstones of management for symptomatic myelofibrosis. Numerous novel agents in development for myelofibrosis, ...
1Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine (Shanghai), Rui-Jin Hospital, Shanghai Jiao Tong University School of ...
Leukemia is a malignant disease of hematopoietic tissue characterized by the differentiation arrest and malignant proliferation of immature hematopoietic precursor cells in bone marrow. ERG ...
All-trans retinoic acid (ATRA) with chemotherapy is the standard of care for acute promyelocytic leukemia (APL), resulting in cure rates exceeding 80%. Pilot studies of treatment with arsenic trioxide ...
Each human chromosome, shown here at a resolution of 400 bands per haploid genome, contains two specialized structures, a centromere and two telomeres. The centromere divides the chromosome into short ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results